Should I add an ACE inhibitor (angiotensin‑converting enzyme inhibitor) or an ARB (angiotensin receptor blocker) before spironolactone in a patient with left ventricular ejection fraction of 50 % whose volume status is controlled on metolazone?

Yes, add an ACE inhibitor or ARB before spironolactone in this patient with LVEF 50%

You should initiate an ACE inhibitor (or ARB if ACE inhibitor is not tolerated) before adding spironolactone, even though fluid status is controlled on metolazone. This patient has heart failure with mildly reduced ejection fraction (HFmrEF), and the evidence strongly supports ACE inhibitor/ARB as foundational therapy that should precede mineralocorticoid receptor antagonist (MRA) therapy.

Rationale Based on Guidelines and Evidence

Why ACE Inhibitor/ARB Should Come First

The most recent 2022 ACC/AHA/HFSA guidelines 1 and 2016 ESC guidelines 2 establish that ACE inhibitors or ARBs are Class I, Level A recommendations for symptomatic heart failure with reduced ejection fraction, forming the cornerstone of guideline-directed medical therapy (GDMT). While your patient's LVEF of 50% technically falls into HFmrEF territory, patients on the lower end of this spectrum (41-49%) respond similarly to HFrEF patients 1.

The 2006 Canadian guidelines 3 explicitly state that ACE inhibitors should be used in all patients with symptoms of heart failure and LVEF less than 40%, with ARBs as alternatives for those intolerant to ACE inhibitors. More importantly, these guidelines note that aldosterone antagonists (spironolactone) should be added to existing therapy - meaning they are adjunctive, not first-line agents.

The Sequencing Matters for Safety

Combining ACE inhibitors/ARBs with spironolactone significantly increases the risk of hyperkalemia and renal dysfunction 3, 4. The Canadian guidelines 3 explicitly warn: "Because combining an ACE inhibitor, ARB and spironolactone together could increase the risk of hyperkalemia, this combination is discouraged unless followed closely in a specialist heart failure clinic."

By establishing ACE inhibitor/ARB therapy first, you can:

• Monitor baseline renal function and potassium levels
• Optimize the dose before adding additional RAAS blockade
• Identify patients who may not tolerate dual RAAS blockade
• Reduce the cumulative risk when spironolactone is eventually added

Spironolactone Indications Are More Restrictive

The evidence for spironolactone is strongest in LVEF ≤35% with NYHA Class III-IV symptoms 3, 5, 6. The 2006 Canadian guidelines 3 specify that aldosterone antagonism should be considered for patients with LVEF <30% and severe symptomatic chronic heart failure despite optimization of other recommended treatments (emphasis on "despite" - meaning after ACE inhibitor/ARB and beta-blocker are already on board).

At LVEF 50%, your patient doesn't meet the traditional criteria for spironolactone unless they have persistent symptoms despite optimal ACE inhibitor/ARB and beta-blocker therapy.

Practical Implementation Algorithm

Step 1: Initiate ACE Inhibitor (or ARB)

• Start with low-dose ACE inhibitor (e.g., enalapril 2.5 mg BID, lisinopril 2.5-5 mg daily, or ramipril 1.25-2.5 mg daily)
• If ACE inhibitor causes intolerable cough or angioedema, substitute with ARB 3, 4
• Check baseline: serum creatinine, potassium, blood pressure (supine and standing) 3

Step 2: Monitor and Uptitrate

• Recheck labs in 1-2 weeks 4
• Accept creatinine increase up to 30% or potassium up to 5.5 mmol/L 4
• Uptitrate to target doses over 4-8 weeks if tolerated
• Reduce metolazone dose if patient becomes euvolemic to minimize hypotension risk 3

Step 3: Add Beta-Blocker

• Once ACE inhibitor/ARB is stable, add evidence-based beta-blocker (bisoprolol, carvedilol, or metoprolol succinate) 2, 1
• This should precede spironolactone in the treatment sequence

Step 4: Consider Spironolactone Only If:

• Patient remains NYHA Class III-IV symptomatic despite ACE inhibitor/ARB + beta-blocker
• Serum creatinine <200 μmol/L (2.26 mg/dL) and potassium <5.2 mmol/L 3
• Start spironolactone 12.5-25 mg daily 6, 7
• Monitor potassium and creatinine closely - weekly initially, then monthly 3, 5

Critical Caveats About Metolazone

The FDA label for metolazone 8 warns that metolazone can cause significant hypokalemia, especially with rapid diuresis. This creates a complex electrolyte management situation:

• Metolazone causes hypokalemia
• ACE inhibitor/ARB causes hyperkalemia
• Spironolactone causes hyperkalemia

The metolazone-induced hypokalemia may be masking the need for potassium-sparing therapy, but jumping straight to spironolactone without establishing ACE inhibitor/ARB first bypasses the proven mortality benefit of RAAS inhibition and increases the risk of dangerous hyperkalemia when you eventually add the ACE inhibitor/ARB.

Mortality and Morbidity Evidence

The evidence hierarchy strongly favors ACE inhibitors/ARBs first:

• ACE inhibitors reduce mortality by 23% in HFrEF (Class I, Level A evidence) 2
• Spironolactone reduces mortality by 30% when added to ACE inhibitor in severe HF 5, 7
• The spironolactone benefit is additive to ACE inhibitor therapy, not a replacement 7, 9

Recent data 1 suggests that in HFmrEF (LVEF 41-49%), ACE inhibitors/ARBs show benefit, while spironolactone evidence is extrapolated from post-hoc analyses and less robust.

Bottom line: Start the ACE inhibitor or ARB now, optimize the dose, then reassess whether spironolactone is truly needed based on persistent symptoms and careful monitoring of renal function and potassium.